CT 1541
Latest Information Update: 11 Nov 1996
Price :
$50 *
At a glance
- Originator Cell Therapeutics
- Class Antineoplastics
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 11 Nov 1996 Discontinued-Preclinical for Cancer in USA (Unknown route)
- 01 Feb 1995 No-Development-Reported for Cancer in USA (Unknown route)